<DOC>
	<DOCNO>NCT00499889</DOCNO>
	<brief_summary>Primary Objective : To estimate probability molecular complete remission one year describe sequential treatment approach , nonablative hematopoietic transplantation , post transplant imatinib mesylate donor lymphocyte infusion , patient Ph-positive Chronic Myelogenous Leukemia ( CML ) blastic transformation . Secondary Objective : Response post transplant Imatinib mesylate therapy 12 week treatment residual disease , response donor lymphocyte infusion ( DLI ) residual disease follow imatinib mesylate therapy , well engraftment , toxicity , disease free survival survival , effect busulfan pharmacokinetics study outcome .</brief_summary>
	<brief_title>Imatinib Mesylate , Busulfan , Fludarabine , Antithymocyte Globulin CML Patients</brief_title>
	<detailed_description>Patients blood bone marrow test perform well chest sinus X-rays test heart lung function . Approximately 5 tablespoon blood drawn . All patient study receive imatinib mesylate mouth 9 day , unless patient know allergic symptomatic intolerance drug , leukemia fail respond imatinib . Fludarabine 40 mg/m2 vein 4 day ( day -5 -2 ) , busulfan 130 mg/m2 vein 2 day ( day -3 -2 ) , ATG ( Antithymocyte Globulin ) 2.5 mg/kg vein 3 day ( -3 , -2 -1 ) . Patients receive donor bone marrow blood stem cell vein approximately one hour day 0 . After infusion donor cell , receive immunosuppressive therapy tacrolimus methotrexate decrease risk develop graft-vs-host disease ( GvHD ) . Patients need frequent blood test monitor count blood chemistry . This generally do daily hospital least twice per week first 100 day post transplant . You may need frequent blood transfusion may admit hospital receive antibiotic develop fever . Bone marrow examine frequently begin four week treatment evaluate response treatment ; Blood bone marrow exam perform one , two three , six , 12 18 month post transplant yearly thereafter 5 year . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Patients treatment produce remission , sign leukemia detect , receive therapy unless leukemia recurs . Patients evidence leukemia 3 month transplant receive additional treatment imatinib mesylate ; detectable leukemia additional 3 month may receive infusion immune cell transplant donor . If evidence leukemia transplant , receive additional treatment imatinib mesylate . If leukemia cell still detect , additional donor immune cell give vein . Patients consider study 5 year transplant . A total 90 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Diagnosis Ph+ chronic myelogenous leukemia ( CML ) first chronic phase without complete hematologic response 3 month Imatinib mesylate therapy , &gt; =35 % Ph+ cell despite &gt; 6 month Imatinib mesylate treatment , disease progression complete partial response . Any patient accelerate phase blast crisis achieve subsequent chronic phase eligible . Patients must HLA match related unrelated donor one antigen mismatch related donor . 2 . Patients le 70 year age . Patients le 30 year age achieve hematologic remission imatinib therapy eligible regardless cytogenetic response . 3 . Patients stratify Group 1 : First chronic phase , Group 2 Accelerated phase blast crisis achieve hematologic remission imatinib mesylatebased treatment . 1 . Zubrod Performance Scale ( PS ) &gt; =2 , uncontrolled infection , Creatinine &gt; 2.0 mg/dl ; Ejection fraction &lt; 40 % ; Carbon Monoxide Diffusing Capacity ( DLCO ) &lt; 45 % predict ; Serum bilirubin &gt; 2 gm/dl ; GPT ( Glutamicpyruvic transaminase ) GOT ( glutamicoxaloacetic transaminase ) &gt; 3 time normal value . Patients human immunodeficiency virus ( HIV ) seropositive pregnant . 2 . Patients progress accelerated phase blast crisis receive imatinib mesylate contain therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>ATG</keyword>
	<keyword>STI571</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Thymoglobulin</keyword>
</DOC>